

Umberto Basso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4825404/publications.pdf>

Version: 2024-02-01

209
papers

12,194
citations

61984

43
h-index

28297

105
g-index

212
all docs

212
docs citations

212
times ranked

14961
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
2	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
3	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	27.0	961
4	Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. <i>Annals of Oncology</i> , 2015, 26, 288-300.	1.2	607
5	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , 2017, 18, 812-822.	10.7	370
6	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	1.6	267
7	Treatment of Estrogen Receptor-Positive Breast Cancer. <i>Current Medicinal Chemistry</i> , 2013, 20, 596-604.	2.4	213
8	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
9	A prospective study on glioblastoma in the elderly. <i>Cancer</i> , 2003, 97, 657-662.	4.1	169
10	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 866-871.	1.6	156
11	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846.	7.0	147
12	Endocrine Therapy of Breast Cancer. <i>Current Medicinal Chemistry</i> , 2011, 18, 513-522.	2.4	140
13	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 5233-5243.	7.0	124
14	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	1.8	116
15	Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004, 22, 4779-4786.	1.6	113
16	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. <i>Cancer</i> , 2004, 100, 1221-1229.	4.1	105
17	First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004, 22, 1598-1604.	1.6	97
18	Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. <i>Bone</i> , 2009, 44, 173-175.	2.9	95

#	ARTICLE	IF	CITATIONS
19	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR wild-type GIST. <i>European Journal of Human Genetics</i> , 2014, 22, 32-39.	2.8	90
20	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 755-761.	0.8	82
21	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 255-258.	1.2	77
22	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	3.2	74
23	Cancer-induced hypercalcemia. <i>Anticancer Research</i> , 2009, 29, 1551-5.	1.1	74
24	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
25	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
26	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
27	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	5.1	68
28	Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective Tissue CANcer NETwork (CONTICANET). <i>Annals of Oncology</i> , 2013, 24, 1685-1691.	1.2	61
29	Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 163-170.	4.4	59
30	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
31	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	1.5	56
32	Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study. <i>Oncology</i> , 2002, 63, 38-41.	1.9	55
33	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1286-1294.	6.4	55
34	Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma. <i>Cell Reports</i> , 2016, 15, 1822-1836.	6.4	55
35	Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. <i>European Journal of Cancer Care</i> , 2004, 13, 424-433.	1.5	52
36	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1069-1077.	2.5	52

#	ARTICLE	IF	CITATIONS
37	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. <i>Oncoscience</i> , 2013, 1, 49-56.	2.2	52
38	Medical Treatment of Malignancy-Associated Hypercalcemia. <i>Current Medicinal Chemistry</i> , 2008, 15, 415-421.	2.4	51
39	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. <i>British Journal of Haematology</i> , 1999, 106, 662-668.	2.5	50
40	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
41	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2005, 16, 1352-1358.	1.2	48
42	Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. <i>Annals of Oncology</i> , 2013, 24, 1093-1098.	1.2	48
43	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009, 18, 106-116.	1.3	45
44	Cells and molecules involved in the development of sarcoid granuloma. <i>Journal of Clinical Immunology</i> , 1998, 18, 184-192.	3.8	44
45	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	2.4	43
46	Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. <i>Annals of Oncology</i> , 2013, 24, 336-342.	1.2	42
47	Management of primary and advanced breast cancer in older unfit patients (medical treatment). <i>Cancer Treatment Reviews</i> , 2009, 35, 503-508.	7.7	41
48	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	2.4	41
49	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-200.	1.6	41
50	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. <i>Annals of Oncology</i> , 2003, 14, 1727-1731.	1.2	38
51	Adjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. <i>Annals of Oncology</i> , 2005, 16, 1276-1282.	1.2	37
52	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L240-L250.	2.9	35
53	FNA cytology and frozen section examination in patients with follicular lesions of the thyroid gland. <i>Anticancer Research</i> , 2009, 29, 5255-7.	1.1	35
54	Malignant Hypercalcemia. <i>Current Medicinal Chemistry</i> , 2011, 18, 3462-3467.	2.4	33

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). <i>World Journal of Surgical Oncology</i> , 2014, 12, 46.	1.9	33
56	Ifosfamide-Related Encephalopathy in Elderly Patients. <i>Drugs and Aging</i> , 2007, 24, 967-973.	2.7	32
57	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
58	Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. <i>European Journal of Cancer</i> , 2002, 38, 1298-1312.	2.8	30
59	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	1.9	30
60	Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. <i>Quality of Life Research</i> , 2013, 22, 369-378.	3.1	28
61	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	3.6	28
62	A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. <i>Neurology</i> , 2002, 58, 1759-1764.	1.1	27
63	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 165-172.	2.9	26
64	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	5.4	25
65	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 146-150.	3.1	25
66	Parathyroid cancer: etiology, clinical presentation and treatment. <i>Anticancer Research</i> , 2006, 26, 4803-7.	1.1	25
67	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. <i>Oncology</i> , 2015, 88, 273-280.	1.9	24
68	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 122.	2.4	24
69	Rectal cancer neoadjuvant treatment in elderly patients. <i>Anticancer Research</i> , 2006, 26, 3913-23.	1.1	24
70	Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 182-189.	1.9	23
71	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	1.2	22
72	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 156-163.	1.0	22

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2016, 6, 253.	2.8	22
74	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
75	Non-cytotoxic therapies for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2002, 58, 57-69.	2.9	21
76	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , 2015, 14, 309-316.	1.9	21
77	High-Dose Chemotherapy with Bone Marrow Rescue for High-Grade Gliomas in Adults. <i>Cancer Investigation</i> , 2001, 19, 41-48.	1.3	20
78	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	4.4	20
79	Which benefit from adding gemcitabine to vinorelbine in elderly (>70 years) women with metastatic breast cancer? Early interruption of a phase II study. <i>Annals of Oncology</i> , 2007, 18, 58-63.	1.2	19
80	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	3.7	19
81	When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients?. <i>Tumori</i> , 2007, 93, 491-492.	1.1	18
82	Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (>70years). <i>Journal of Geriatric Oncology</i> , 2013, 4, 340-345.	1.0	18
83	Targeted Approaches to Triple-Negative Breast Cancer: Current Practice and Future Directions. <i>Current Medicinal Chemistry</i> , 2013, 20, 605-612.	2.4	18
84	Vulnerable and frail elderly: An approach to the management of the main tumour types. <i>European Journal of Cancer</i> , 2008, 44, 488-493.	2.8	17
85	Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 187-201.	1.6	17
86	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	2.5	17
87	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	1.1	17
88	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	3.1	17
89	Oncological causes of frailty in older cancer patients. <i>European Journal of Cancer</i> , 2007, 43, 1230-1231.	2.8	16
90	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e161-e169.	1.9	16

#	ARTICLE	IF	CITATIONS
91	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Supportive Care in Cancer, 2020, 28, 4687-4695.	2.2	16
92	New Strategy Developments in Brain Tumor Therapy. Current Pharmaceutical Design, 2001, 7, 1553-80.	1.9	15
93	Is intra-arterial chemotherapy useful in high-grade gliomas?. Expert Review of Anticancer Therapy, 2002, 2, 507-519.	2.4	15
94	Cost of illness of urothelial bladder cancer in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 433-442.	1.9	15
95	International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26. BMC Cancer, 2018, 18, 1104.	2.6	15
96	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	1.9	15
97	Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. Anticancer Research, 2008, 28, 1383-8.	1.1	15
98	Sorafenib is active on lung metastases from synovial sarcoma. Annals of Oncology, 2009, 20, 386-387.	1.2	14
99	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clinical Genitourinary Cancer, 2016, 14, 48-55.	1.9	14
100	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. Clinical Genitourinary Cancer, 2019, 17, e187-e194.	1.9	14
101	Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. Anticancer Research, 2015, 35, 543-7.	1.1	14
102	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer, 2017, 1, 41-47.	0.4	13
103	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. Diagnostics, 2021, 11, 138.	2.6	13
104	Treatment options for early breast cancer in elderly women. Expert Review of Anticancer Therapy, 2004, 4, 197-211.	2.4	12
105	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncology, 2015, 11, 2881-2891.	2.4	12
106	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights: Oncology, 2021, 15, 117955492110216.	1.3	12
107	Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. Anticancer Research, 2014, 34, 5251-62.	1.1	12
108	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. Expert Review of Anticancer Therapy, 2003, 3, 615-620.	2.4	11

#	ARTICLE	IF	CITATIONS
109	Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. <i>Journal of Geriatric Oncology</i> , 2021, 12, 290-297.	1.0	11
110	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	1.4	11
111	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 461-467.	2.7	10
112	Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas. <i>Current Medicinal Chemistry</i> , 2013, 20, 613-620.	2.4	10
113	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 965-973.	2.4	10
114	Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes. <i>European Journal of Surgical Oncology</i> , 2017, 43, 401-406.	1.0	10
115	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	3.7	10
116	Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103579.	4.4	10
117	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
118	Changing boundaries in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 357-370.	2.4	9
119	Determining Therapeutic Approaches in the Elderly with Rectal Cancer. <i>Drugs and Aging</i> , 2007, 24, 781-790.	2.7	9
120	Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. <i>Anti-Cancer Drugs</i> , 2016, 27, 264-267.	1.4	9
121	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	2.4	9
122	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, 137-145.e4.	2.4	9
123	Estrogen therapy and risk of breast cancer in postmenopausal women. <i>Menopause</i> , 2010, 17, 524-528.	2.0	9
124	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). <i>Frontiers in Oncology</i> , 2021, 11, 787835.	2.8	9
125	Adjuvant treatment for elderly patients with colon cancer. An observational study. <i>Anticancer Research</i> , 2008, 28, 2513-8.	1.1	9
126	Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A caseâ€control study. <i>Biomedicine and Pharmacotherapy</i> , 2002, 56, 416-420.	5.6	8

#	ARTICLE	IF	CITATIONS
127	Management of muscle-invasive bladder cancer in the elderly. Expert Review of Anticancer Therapy, 2004, 4, 1017-1035.	2.4	8
128	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. Future Oncology, 2016, 12, 493-502.	2.4	8
129	Recommendations for the management of malignant gliomas in the elderly. Expert Review of Anticancer Therapy, 2003, 3, 643-654.	2.4	7
130	Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With Everolimus. American Journal of Therapeutics, 2016, 23, e300-e303.	0.9	7
131	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2016, 142, 679-685.	2.5	7
132	Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. Anticancer Research, 2011, 31, 693-7.	1.1	7
133	Metastatic malignant soft tissue myoepithelioma: a case report showing complete response after locoregional and systemic therapy. Journal of Surgical Case Reports, 2013, 2013, rjt109-rjt109.	0.4	6
134	Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. Anti-Cancer Drugs, 2014, 25, 1227-1230.	1.4	6
135	Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer, 2016, 16, 752.	2.6	6
136	Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters. Frontiers in Oncology, 2021, 11, 626104.	2.8	6
137	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	3.6	6
138	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. Journal of Clinical Oncology, 2014, 32, 5089-5089.	1.6	6
139	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. Cancers, 2022, 14, 2568.	3.7	6
140	New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Expert Review of Anticancer Therapy, 2005, 5, 53-62.	2.4	5
141	Cancer in the elderly. Internal and Emergency Medicine, 2011, 6, 115-118.	2.0	5
142	Is It Possible That One Patient May Again Experience a Response to Abiraterone Acetate Withdrawal During an Abiraterone Acetate Rechallenge?. European Urology, 2014, 66, 179-180.	1.9	5
143	A Solitary Metastasis for a Malignant Schwannoma in the Gallbladder Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine, 2016, 41, 666-667.	1.3	5
144	Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5â€%ng/ml. Nuclear Medicine Communications, 2018, 39, 260-267.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 154-164.	4.4	5
146	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020, 6, 65.	4.7	5
147	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5030-5030.	1.6	5
148	Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. <i>Anticancer Research</i> , 2007, 27, 1079-85.	1.1	5
149	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , 2011, 73, 78-88.	2.0	4
150	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 909-919.	2.4	4
151	Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 553.	2.8	4
152	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4568-4568.	1.6	4
153	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). <i>Immunotherapy</i> , 2022, 14, 107-114.	2.0	4
154	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	1.1	4
155	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	3.7	4
156	Controversies in the therapy of low-grade glioma: when and how to treat. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 529-536.	2.4	3
157	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 167-178.	2.4	3
158	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , 2017, 43, 110-116.	1.5	3
159	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	2.4	3
160	Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 222-225.	1.4	3
161	Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4577-4577.	1.6	3
162	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3

#	ARTICLE	IF	CITATIONS
163	Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. Targeted Oncology, 2022, 17, 467-474.	3.6	3
164	Do older women with breast cancer benefit from adjuvant chemotherapy?. Nature Clinical Practice Oncology, 2006, 3, 652-653.	4.3	2
165	Oligonucleotide Probe Array for p53 Gene Alteration Analysis in DNA from Formalin-Embedded Breast Cancer Tissues. Annals of the New York Academy of Sciences, 2009, 1175, 89-92.	3.8	2
166	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. Annals of Oncology, 2016, 27, vi252.	1.2	2
167	To Transplant or Not to Transplant During the SARS-CoV-2 Pandemic? That Is the Question. Oncologist, 2021, 26, e336-e337.	3.7	2
168	Association of body surface area with fat mass, free fat mass and total weight in healthy individuals, and implications for the dosage of cytotoxic drugs. Clinical Nutrition ESPEN, 2021, 43, 471-477.	1.2	2
169	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. Journal of Clinical Oncology, 2014, 32, 92-92.	1.6	2
170	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World Journal of Clinical Oncology, 2021, 12, 1037-1046.	2.3	2
171	Axillary lymph node metastases detection with 99mTc-sestamibi scintimammography in patients with breast cancer undergoing curative surgery. Anticancer Research, 2007, 27, 2949-52.	1.1	2
172	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 825-832.	0.8	2
173	Temozolomide in Glioblastoma Multiforme of the Elderly. Tumori, 2002, 88, S69-S70.	1.1	1
174	2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma. European Journal of Cancer, 2015, 51, S511-S512.	2.8	1
175	OECI Accreditation at Veneto Institute of Oncology IOV - IRCCS, General Framework and Multidisciplinary Approach. Tumori, 2015, 101, S38-S41.	1.1	1
176	More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis. Annals of Oncology, 2016, 27, 202-203.	1.2	1
177	Abstract 1723: Diagnostic leukapheresis results in a significant increase in CTC yield in metastatic breast and prostate cancer. , 2017, , .		1
178	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. Journal of Clinical Oncology, 2014, 32, 253-253.	1.6	1
179	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2016, 34, 4570-4570.	1.6	1
180	Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database.. Journal of Clinical Oncology, 2018, 36, e17007-e17007.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.. Journal of Clinical Oncology, 2012, 30, 411-411.	1.6	1
182	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. Journal of Clinical Oncology, 2016, 34, 547-547.	1.6	1
183	Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic castrate resistant prostate cancer (mCRPC): A feasibility study.. Journal of Clinical Oncology, 2018, 36, 367-367.	1.6	1
184	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit"™ study. Japanese Journal of Clinical Oncology, 2021, 51, 484-491.	1.3	1
185	Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. Anticancer Research, 2008, 28, 491-3.	1.1	1
186	Overprotective Caregivers of Elderly Cancer Patients: A Case Report. Tumori, 2006, 92, 362-363.	1.1	0
187	Thyroid C-Cell Hyperplasia Shown by Combined In-111 Pentetretotide, Tc-99m Pertechnetate, and Tc-99m MIBI Scintigraphy. Clinical Nuclear Medicine, 2007, 32, 378-379.	1.3	0
188	Nutritional Habits and Body Mass Index in the Elderly Population: Can This Information Be Useful Before Planning Chemotherapy Administration in Older Cancer Patients?. Nutrition and Cancer, 2008, 60, 552-554.	2.0	0
189	Adjuvant! Online or comprehensive geriatric assessment for women over 70 years with primary breast cancer?. British Journal of Cancer, 2012, 106, 1247-1247.	6.4	0
190	2627 Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): Results of the European observational study EPICURE. European Journal of Cancer, 2015, 51, S521.	2.8	0
191	Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).. Journal of Clinical Oncology, 2012, 30, 220-220.	1.6	0
192	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. Journal of Clinical Oncology, 2013, 31, 189-189.	1.6	0
193	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. Journal of Clinical Oncology, 2013, 31, 90-90.	1.6	0
194	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. Journal of Clinical Oncology, 2013, 31, 208-208.	1.6	0
195	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	1.6	0
196	Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. Journal of Clinical Oncology, 2014, 32, 374-374.	1.6	0
197	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. Journal of Clinical Oncology, 2014, 32, e15588-e15588.	1.6	0
198	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. Journal of Clinical Oncology, 2014, 32, e15563-e15563.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2015, 33, 216-216.	1.6	0
200	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2015, 33, 206-206.	1.6	0
201	Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).. Journal of Clinical Oncology, 2015, 33, e16045-e16045.	1.6	0
202	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. Journal of Clinical Oncology, 2015, 33, e15595-e15595.	1.6	0
203	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. Journal of Clinical Oncology, 2016, 34, 210-210.	1.6	0
204	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.. Journal of Clinical Oncology, 2016, 34, 325-325.	1.6	0
205	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. Journal of Clinical Oncology, 2016, 34, 549-549.	1.6	0
206	Chemotherapy (CT) for advanced soft tissue sarcoma (STS) in older patients (pts): Toxicity and outcomes in a single center experience.. Journal of Clinical Oncology, 2016, 34, e21527-e21527.	1.6	0
207	Rectal cancer adjuvant chemotherapy: when is more useful?. Anticancer Research, 2008, 28, 1805-12.	1.1	0
208	Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus. Anticancer Research, 2008, 28, 4095-100.	1.1	0
209	Role of neoadjuvant treatment in cT3N0M0 rectal cancer. Anticancer Research, 2008, 28, 4129-35.	1.1	0